• Explore /
  • Poster
  • / BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).

BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).

Abstract Poster

Authors

Ana Oaknin

Ana Oaknin

Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Ana Oaknin , Laurence Gladieff , Nicoletta Colombo , Guillermo Villacampa , Mansoor Raza Mirza , Ugo De Giorgi , Leslie M. Randall , Munetaka Takekuma , Antonio González-Martín

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT03556839

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS5594)

DOI

10.1200/JCO.2019.37.15_suppl.TPS5594

Abstract #

TPS5594

Poster Bd #

417a

Abstract Disclosures

Similar Posters

First Author: Ronnie Shapira-Frommer

First Author: Thierry Landre

First Author: Jianqing Zhu

First Author: Patrick M. Forde